Jessilin Quint, OD, MBA, MS, FAAO, shares the latest and greatest in the world of dry eye, from new technology to how clinicians can start in on dry eye therapy today.
Mark Bullimore, MCOptom, PhD, FAAO, discussed myopia control in a panel at EyeCon 2023, highlighting evidence-based treatments, myopia's impact on visual impairment, and a multidisciplinary conversation involving optometrists and ophthalmologists to address the growing issue of myopia management.
Bringing awareness, understanding, and embracing mental health care gives clinicians the space to best support and empower their patients, as well as themselves.
Imaging shows optic disc swelling and retinal nerve fiber layer thickening
Catherine L. Heyman, OD, FAAO, FCOVD, shares highlights from her AOA 2022 presentation, "Evaluation and Management of Patients with Special Needs."
Real-time insights into fluctuations enhance glaucoma care and understanding of vision risk.
Low-lying lids affect much more than patients' visual field, with implications for visual quality and their self-esteem.
Contoured prism lenses may resolve symptoms such as neck, shoulder, and head pain.
With advanced, easy-to-fit multifocal lens technologies, patients don’t need to compromise
Jim Sluck, VP of Marketing for Sight Sciences' TearCare, shares the impetus behind the company's fair access campaign.
Studies conducted with Orbis International conclude positive mental health and academic improvements of children provided appropriate eye care and glasses, filling important research gaps and providing essential guidance for future interventions and research.
At NOA 2023 in Fort Lauderdale, Florida, Rhea Magee, OD, presented a pediatric patient case as part of the Resident Grand Rounds.
How to fit lenses with simple devices and when to expand your armature.
John Berdahl, MD, discussed the Aurion clinical trials of endothelial cell therapy injection at the 2023 ASCRS annual meeting in San Diego.
Optometry Times sat down with Carla Calizaire, Global Leader of Diversity Inclusion for Johnson and Johnson Med Tech to go in depth about the Vision Made Possible and Sight for Kids campaign.
The Phase 1/2 study includes a dose-escalation phase of the study featuring 3 cohorts each one receiving either a low, medium, or high dose of OCU410.
Lisa Hornick, OD, MBA, FAAO, chats about her AAOpt presentations, "Dry Eye Jeopardy" and "Sunny with a Chance of Tears of Tears: What's in the Forecast for Ocular Surface Dryness Therapies."
The CHAMP phase 3 study shows strong safety and efficacy of NVK002 for the treatment of myopia.
Pediatric glaucoma, although rare, can cause irreversible vision loss and leave children visually impaired if not treated timely and adequately.
Consider the impact of diabetes on management of patients with glaucoma
Combining products and resources in creative ways can help grow your business.
Doctors should consider a few key points before writing a prescription.
Addressing issues prior to referral will facilitate the referral process and enable more efficient care for your patient as well as maximize outcomes.
Clinical benefit of complement inhibition has been demonstrated in clinical trials, but there are possible consequences to consider.
Two key points to remember when fitting
Regarding both the amount and speed of symptom improvement, patients were more satisfied with the insert compared with the topical steroid, but there was no statistically significant difference vs the topical antihistamine in terms of satisfaction.